Exagen (XGN) Return on Equity (2019 - 2025)
Historic Return on Equity for Exagen (XGN) over the last 7 years, with Q3 2025 value amounting to 0.97%.
- Exagen's Return on Equity rose 1400.0% to 0.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.97%, marking a year-over-year increase of 1400.0%. This contributed to the annual value of 0.94% for FY2024, which is 2100.0% down from last year.
- According to the latest figures from Q3 2025, Exagen's Return on Equity is 0.97%, which was up 1400.0% from 1.24% recorded in Q2 2025.
- Exagen's Return on Equity's 5-year high stood at 0.21% during Q2 2021, with a 5-year trough of 1.95% in Q1 2025.
- Moreover, its 5-year median value for Return on Equity was 0.94% (2023), whereas its average is 0.86%.
- Per our database at Business Quant, Exagen's Return on Equity soared by 2700bps in 2024 and then crashed by -10400bps in 2025.
- Exagen's Return on Equity (Quarter) stood at 0.31% in 2021, then crashed by -222bps to 0.98% in 2022, then increased by 4bps to 0.94% in 2023, then plummeted by -43bps to 1.35% in 2024, then increased by 28bps to 0.97% in 2025.
- Its Return on Equity was 0.97% in Q3 2025, compared to 1.24% in Q2 2025 and 1.95% in Q1 2025.